Primary systemic therapy of breast cancer
References
Fisher B, Gunduz N, Coyle J et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001
Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237.
Gianni L, Baselga L, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11: 8715-8721.
Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
Scholl SM, Fourquet A, Asselain B et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-652.
Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-1184.
Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-194.
Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006;24:2019-2027.
Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(suppl 2):S69-S74.
von Minckwitz G,Blohmer JU, Loehr A et al. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy-first results of the phase III GEPARTRIO-Study by the German Breast Group. San Antonio Breast Cancer Symposium 2005, San Antonio, Texas, December 8-12, 2005
von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685.
Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer : an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988-2995.
Untch M, Konecny G, Ditsch N et al. Dose-dense sequential epirubicinpaclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 2002;21:133a.
Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
Jones RL, Smith IE.Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response.Lancet Oncol 2006;7:869-74.
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-9.
Buzdar A, Valero V, Theriault R et al. Pathologic complete response to chemotherapy is related to hormone receptor status. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10: 6622-6628.
Ring AE, Smith IE, Ashley S et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91:2012-2017.
Gianni L, Zambetti M, Clark K et al. Gene expression profiles of paraffin embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 2004;23:501a.
Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-48.
Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.Expert Opin Pharmacother 2005;6:1477-91.
Perou CM, Jeffrey SS, van de Rijn M, Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.Proc Natl Acad Sci U S A. 1999;96:9212-7.
S?rlie T, Perou CM, Tibshirani R, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74.
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678-85.
Buchholz TA, Stivers DN, Stec J, et al.Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002;8:461-8.
Chang JC, Wooten EC, Tsimelzon A, et al.Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
Ayers M, Symmans WF, Stec J, et al.Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.J Clin Oncol 2004;22:2284-93.
Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31.
Thuerigen O, Schneeweiss A, Toedt G, et al.Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006 Apr 20;24(12):1839-45.
Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor
receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-20.
Semiglazov VF, Ivanov VG, Ziltzova EK et al. The relative efficacy of neoadjuvant endocrine therapy versus chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 2004;23:519a.
Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrazole, tamoxifen, or both in combination: the Immediate Preoperative Anastrazole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter
double-blind randomized trial. J Clin Oncol 2005;23:5108-5116.
Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine chemotherapy than tamoxifen for erbB-1-and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol 2001;19:3808-3816.
Semiglazov VF, Kletsel AE, Semiglazov VV et al. Exemestane versus tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER positive breast cancer (T2N1-2, T3N0-1, T4N0M0). Proc Am Soc Clin Oncol 2005;24:530a.
Cleator S, Heller W, Coombes RC.Triple-negative breast cancer: therapeutic options. Lancet Oncolol 2007;8(3):235-44.
Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493.
van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-4237.
Gianni L, Baselga L, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11: 8715-8721.
Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999;10:47-52.
Scholl SM, Fourquet A, Asselain B et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994;30A:645-652.
Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998;9:1179-1184.
Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-194.
Bear HD, Anderson S, Smith RE et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006;24:2019-2027.
Heys SD, Hutcheon AW, Sarkar TK et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 2002;3(suppl 2):S69-S74.
von Minckwitz G,Blohmer JU, Loehr A et al. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy-first results of the phase III GEPARTRIO-Study by the German Breast Group. San Antonio Breast Cancer Symposium 2005, San Antonio, Texas, December 8-12, 2005
von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-2685.
Evans TR, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer : an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005;23:2988-2995.
Untch M, Konecny G, Ditsch N et al. Dose-dense sequential epirubicinpaclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study. Proc Am Soc Clin Oncol 2002;21:133a.
Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-5992.
Jones RL, Smith IE.Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response.Lancet Oncol 2006;7:869-74.
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24:1940-9.
Buzdar A, Valero V, Theriault R et al. Pathologic complete response to chemotherapy is related to hormone receptor status. San Antonio Breast Cancer Symposium 2003, San Antonio, Texas, December 3-6, 2003.
Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004;10: 6622-6628.
Ring AE, Smith IE, Ashley S et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91:2012-2017.
Gianni L, Zambetti M, Clark K et al. Gene expression profiles of paraffin embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer. Proc Am Soc Clin Oncol 2004;23:501a.
Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-48.
Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.Expert Opin Pharmacother 2005;6:1477-91.
Perou CM, Jeffrey SS, van de Rijn M, Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.Proc Natl Acad Sci U S A. 1999;96:9212-7.
S?rlie T, Perou CM, Tibshirani R, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74.
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5678-85.
Buchholz TA, Stivers DN, Stec J, et al.Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002;8:461-8.
Chang JC, Wooten EC, Tsimelzon A, et al.Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
Ayers M, Symmans WF, Stec J, et al.Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.J Clin Oncol 2004;22:2284-93.
Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31.
Thuerigen O, Schneeweiss A, Toedt G, et al.Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006 Apr 20;24(12):1839-45.
Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor
receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685.
Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-20.
Semiglazov VF, Ivanov VG, Ziltzova EK et al. The relative efficacy of neoadjuvant endocrine therapy versus chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 2004;23:519a.
Smith IE, Dowsett M, Ebbs SR et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrazole, tamoxifen, or both in combination: the Immediate Preoperative Anastrazole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter
double-blind randomized trial. J Clin Oncol 2005;23:5108-5116.
Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine chemotherapy than tamoxifen for erbB-1-and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol 2001;19:3808-3816.
Semiglazov VF, Kletsel AE, Semiglazov VV et al. Exemestane versus tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER positive breast cancer (T2N1-2, T3N0-1, T4N0M0). Proc Am Soc Clin Oncol 2005;24:530a.
Cleator S, Heller W, Coombes RC.Triple-negative breast cancer: therapeutic options. Lancet Oncolol 2007;8(3):235-44.
Downloads
Published
2008-06-30
How to Cite
1.
เจริญธรรม ช. Primary systemic therapy of breast cancer. J Thai Assn of Radiat Oncol [Internet]. 2008 Jun. 30 [cited 2024 Nov. 15];14(1):27-43. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/203560
Issue
Section
Original articles
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
